Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

@article{Kotloff2004DeletionIT,
  title={Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.},
  author={Karen L. Kotloff and Marcela F Pasetti and Eileen M. Barry and James P Nataro and Steven S. Wasserman and Marcelo B. Sztein and William D. Picking and Myron M. Levine},
  journal={The Journal of infectious diseases},
  year={2004},
  volume={190 10},
  pages={1745-54}
}
BACKGROUND We created a live, attenuated, oral Shigella vaccine by constructing a lineage of guanine auxotrophs and conducted a double-blind, placebo-controlled trial to ascertain (1) the attenuation profile of Delta guaBA Shigella flexneri 2a, which harbors deletions in the guanine nucleotide synthesis pathway (CVD 1204); (2) additional attenuation conferred by deletions in set and sen genes encoding Shigella enterotoxins (ShETs) 1 and 2, respectively (CVD 1208); and (3) the relative… CONTINUE READING